LGD-4033 (Ligandrol) — Research Literature Summary
✓ Verified dosing (fact-checked against FDA labels / published trials): No FDA-approved dose exists (investigational only). The sole human-trial dosing is from Basaria 2013 Phase 1: 0.1-1.0 mg orally once daily for 21 days, with 1.0 mg/day being the highest dose ever studied. Route (oral) and frequency (once daily, justified by ~24-36 h half-life) are correct. There is NO validated human basis for 5-10 mg, for 8-12 week… This supersedes any conflicting figures shown elsewhere on this page; confirm with a licensed provider.
Class: SARM • Page type: research-literature reference • Updated 2026-04-23
Regulatory notice — research reference only
LGD-4033 is an investigational SARM that has not been approved for human use by any regulatory authority. The U.S. FDA and DOJ have explicitly enforced against sale of SARMs for human consumption. This page summarizes published preclinical and Phase I research literature only.
Published research summary
- See the canonical LGD-4033 research summary page.
- LGD-4033 is an orally bioavailable nonsteroidal SARM with documented HPT-axis suppression at doses greater than or equal to 1 mg/day in 21-day trials.
Why this page does not publish a consumer “cycle” schedule
No peer-reviewed support exists for consumer 'cycle' or 'PCT' protocols beyond the 21-day and 12-week fixed-dose trials above.
Peer-reviewed citations
Consulting a healthcare provider: This page is a reference for published research. If you are considering any health decision, consult a licensed healthcare provider. Path to Peptides does not provide medical advice.
⚠ Before any use: human safety data is limited or absent for many of these compounds. Consult a licensed healthcare provider first — especially if you are pregnant or nursing, have a medical condition, or take other medications.